A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Protagonist Therapeutics, Inc. PTGX
Mixed broader-coverage candidate · Protagonist Therapeutics, Inc.
On FrontierLab's discovery record since 2026-08-13 (7 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-09-22), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 34.8% |
|---|---|
| Gross margin | 99.9% |
| Gross profits / assets | 0.32 |
| Rule of 40 | 55.5 |
| Net margin | 20.7% |
| Cash runway (months) | — |
| PEG | 2.9 |
| Price / sales | 33.1 |
Quality checklist
- ~ Revenue growth — 34.8% (pass ≥ 20%)
- ~ Gross profits / assets — 0.32 (pass ≥ 0.33)
- ✓ Gross margin — 99.9% (pass ≥ 60%)
- ✓ Cash generation
- ✗ Share dilution — 11.8%
Fundamentals — snapshot as of 2026-09-22
| Stage | Established |
|---|---|
| Share issuance (YoY) | 11.8% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | 140.3 |
| EPS (trailing) | $1.03 |
| Burn multiple | — |
| Gross-margin trend (pts) | -0.1 |
| Cash / assets | 0.88 |
| Net debt / EBITDA | -4.8 |
| Statements as of | Q2 FY2026 · filed 2026-08-05 |
Momentum context — a snapshot from 2026-09-22, not current
| Price at surface | $144.98 (as of 2026-09-22) |
|---|---|
| 52-week range | $62.24 – $160.81 |
| % off 52-wk high | -9.8% |
| RSI (14) | 49 |
| Relative volume | 1.2× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-09-22 (end-of-day). How grades are computed →